سعر انكسنيل 0.5 مجم / 5 مل 5 أمبول 2022

Intravenous injection of flumazenil 0.5 mg/5 ml (0.1 mg/ml), a benzodiazepine antagonist used as an antidote (Anexnil, Delta Pharma, Egypt); 5 ampoules. The source list marks it "(n/a)" (possibly not available).

• Complete or partial reversal of benzodiazepine sedation after general anaesthesia or diagnostic/therapeutic proceduresPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Management of benzodiazepine overdosePopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Reversal of conscious sedation induced with benzodiazepinesPopulation: Paediatric patients aged 1 to 17 yearsDailyMed (U.S. National Library of Medicine)

• Most common: nausea and vomiting (11%), dizziness (10%), injection-site pain, agitation, sweating, headache, abnormal or blurred vision.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Serious: convulsions (<1%), benzodiazepine withdrawal symptoms, arrhythmias.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to flumazenil or to benzodiazepines.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Patients given a benzodiazepine to control a potentially life-threatening condition (e.g. raised intracranial pressure, status epilepticus).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Patients showing signs of serious cyclic antidepressant overdose.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: seizures have been associated with flumazenil, particularly in long-term benzodiazepine users and in serious cyclic antidepressant overdose; individualise dosing and be prepared to manage seizures.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Resedation and hypoventilation may occur because flumazenil is shorter-acting than many benzodiazepines; monitor for up to 120 minutes.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Does not reverse the effects of opioids; high risk of seizures or resedation in patients with benzodiazepine dependence (including after a few days of high-dose ICU sedation); not recommended in epileptic patients on prolonged benzodiazepine treatment; may provoke panic attacks in patients with panic disorder.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Cyclic (tricyclic) antidepressants / mixed overdoseToxic effects (seizures, arrhythmias) of other drugs taken in overdose may emerge when benzodiazepine effects are reversed.DailyMed (U.S. National Library of Medicine)
• Non-benzodiazepine agonists at benzodiazepine receptors (zopiclone, triazolopyridazines)Their effects are also blocked by flumazenil.DailyMed (U.S. National Library of Medicine)
• EthanolNo pharmacokinetic interaction with ethanol; flumazenil does not reverse ethanol effects.DailyMed (U.S. National Library of Medicine)

• No adequate and well-controlled studies in pregnant women; use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Not recommended during labour and delivery.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Excretion in human milk is unknown; use with caution in nursing mothers.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Flumazenil: Blocks the central effects of benzodiazepines by competitive interaction at the benzodiazepine receptor; also blocks non-benzodiazepine agonists at that receptor (e.g. zopiclone) but does not reverse opioids, ethanol or barbiturates.